Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy

Erik J. Novak, Consuelo M. Blosch, James D. Perkins, Connie L. Davis, Darlene Barr, John McVicar, Rachael S. Griffin, Allen L. Farrand, Mark Wener, Christopher L. Marsh

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background. Initial doses of OKT3 are associated with a cytokine- induced acute clinical syndrome (ACS). This study assessed the safety of a recombinant human tumor necrosis factor receptor fusion protein (TNFR:Fc) given to minimize OKT3-ACS symptoms in renal allograft recipients undergoing induction therapy. Methods. Sixteen patients were randomized into treatment or control groups. Treated patients received TNFR:Fc I hr before OKT3 on days 0 and 3. Patients were monitored after transplant for OKT3-ACS symptoms. Levels of cytokines, serum creatinine, and C-reactive protein were followed. Results. Patients receiving TNFR:Fc had lower OKT3-ACS symptoms as measured by a scoring system. There was a higher incidence of infection in treated patients (10/12) compared to controls (1/4) in the 3 months after transplant, but the etiology of this difference was unclear. There were no significant differences in cytokine profiles. Conclusions. TNFR:Fc is well tolerated by renal transplant patients receiving OKT3 induction therapy and modestly decreases the symptoms associated with OKT3-ACS.

Original languageEnglish (US)
Pages (from-to)1732-1735
Number of pages4
JournalTransplantation
Volume66
Issue number12
DOIs
StatePublished - Dec 27 1998
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy'. Together they form a unique fingerprint.

  • Cite this

    Novak, E. J., Blosch, C. M., Perkins, J. D., Davis, C. L., Barr, D., McVicar, J., Griffin, R. S., Farrand, A. L., Wener, M., & Marsh, C. L. (1998). Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy. Transplantation, 66(12), 1732-1735. https://doi.org/10.1097/00007890-199812270-00028